Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Tarsus Pharmaceuticals Inc (TARS)

Tarsus Pharmaceuticals Inc (TARS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Tarsus Pharmaceuticals Inc 15440 LAGUNA CANYON ROAD SUITE 160 IRVINE CA 92618 USA

www.tarsusrx.com P: 949-418-1801

Description:

Tarsus Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It is focused on the development and commercialization of therapeutic candidates to address ophthalmic conditions. The company's product candidate consist TP-03 which is in clinical stage. Tarsus Pharmaceuticals Inc. is based in IRVINE, Calif.

Key Statistics

Overview:

Market Capitalization, $K 1,444,784
Enterprise Value, $K 1,249,654
Shares Outstanding, K 37,782
Annual Sales, $ 17,450 K
Annual Net Income, $ -135,890 K
Last Quarter Sales, $ 27,610 K
Last Quarter Net Income, $ -35,730 K
EBIT, $ -155,890 K
EBITDA, $ -157,790 K
60-Month Beta 1.10
% of Insider Shareholders 11.54%
% of Institutional Shareholders 90.01%
Float, K 33,422
% Float 88.46%
Short Volume Ratio 0.74

Growth:

1-Year Return 140.05%
3-Year Return 19.76%
5-Year Return 0.00%
5-Year Revenue Growth 0.00%
5-Year Earnings Growth 0.00%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -1.01 on 05/08/24
Latest Earnings Date N/A
Earnings Per Share ttm -4.77
EPS Growth vs. Prev Qtr 22.90%
EPS Growth vs. Prev Year -14.77%
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%

TARS Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -71.12%
Return-on-Assets % -55.30%
Profit Margin % -778.74%
Debt/Equity 0.11
Price/Sales 83.55
Price/Cash Flow N/A
Price/Book 5.30
Book Value/Share 7.28
Interest Coverage -39.56
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar